The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers
Open accessAbstract
Background: Recent reports indicate that prostate cancers (CaP) frequently over-express the potential oncogenes, ERG or ETV1 . Many cases have chromosomal rearrangements leading to the fusion of the 5′ end of the androgen-regulated serine protease TMPRSS2 (21q22.2) to the 3′ end of either ERG (21q22.3) or ETV1 (7p21.3). The consequence of these rearrangements is aberrant androgen receptor-driven expression of the potential oncogenes, ETV1 or ERG . Aim: To determine the frequency of rearrangements involving TMPRSS2 , ERG , or ETV1 genes in CaP of varying Gleason grades through fluorescence in situ hybridisation (FISH) on CaP tissue microarrays (TMAs). Methods: Two independent assays, a TMPRSS2 break-apart assay and a three-colour gene fusion FISH assay were applied to TMAs. FISH positive cases were confirmed by reverse transcriptase (RT) PCR and DNA sequence analysis. Results: A total of 106/196 (54.1%) cases were analysed by FISH. None of the five benign prostatic hyperplasia cases analysed exhibited these gene rearrangements. TMPRSS2:ERG fusion was found more frequently in moderate to poorly differentiated tumours (35/86, 40.7%) than in well differentiated tumours (1/15, 6.7%, p = 0.017). TMPRSS2:ETV1 gene fusions were not detected in any of the cases tested. TMPRSS2:ERG fusion product was verified by RT-PCR followed by DNA sequencing in 7/7 randomly selected positive cases analysed. Conclusion: This study indicates that TMPRSS2:ERG gene rearrangements in CaP may be used as a diagnostic tool to identify prognostically relevant sub-classifications of these cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Research works printed but not linked: 32
- 10.3322/canjclin.56.2.106 · DOI · Paper page
- Taki, 2006, Chromosomal translocations in cancer and their relevance for therapy., Curr Opin Oncol, 18, 62, 10.1097/01.cco.0000198972.69541.04 · DOI
- 10.1038/sj.onc.1208892 · DOI
- 10.1002/ajmg.10694 · DOI
- 10.1159/000019907 · DOI
- 10.1023/A:1015575125780 · DOI · Paper page
- 10.1002/(SICI)1097-0045(19990301)38:4<303::AID-PROS6>3.0.CO;2-E · DOI
- 10.1038/sj.onc.1208518 · DOI · Paper page
- 10.1002/gcc.20329 · DOI · Paper page
- 10.1593/neo.06283 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-1966 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-1482 · DOI · Paper page
- 10.1097/01.mou.0000193389.31727.9b · doi:10.1097/01.mou.0000193389.31727.9b
- 10.1158/0008-5472.CAN-04-2446 · DOI · Paper page
- 10.1158/0008-5472.CAN-03-3998 · DOI · Paper page
- 10.1002/gcc.20028 · doi:10.1002/gcc.20028
- 10.1073/pnas.0507321103 · DOI · Paper page
- 10.1007/s10024-002-0013-1 · doi:10.1007/s10024-002-0013-1
- 10.1038/sj.onc.1203762 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-0168 · DOI · Paper page
- 10.1200/JCO.2005.03.3134 · DOI · Paper page
- 10.1200/JCO.2005.02.7987 · doi:10.1200/jco.2005.02.7987
- 10.1002/ijc.1526 · doi:10.1002/ijc.1526
- 10.1016/S0959-8049(01)00077-6 · DOI
- 10.1016/S0378-1119(02)01156-3 · DOI · Paper page
- 10.1002/cncr.20243 · doi:10.1002/cncr.20243
- 10.1038/sj.onc.1210070 · DOI · Paper page
- 10.1038/nature06024 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-1986 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-1871 · DOI · Paper page
- 10.1097/01.ju.0000139993.51181.5d · DOI · Paper page
- 10.1158/1078-0432.CCR-06-0067 · DOI · Paper page
Cited by
Role of the TMPRSS2-ERG Gene Fusion in Prostate Cancer
Tomlins, S. A., Laxman, B., Varambally, S., Cao, X., Yu, J., Helgeson, B. E., Cao, Q., Prensner, J. R., Rubin, M. A., Shah, R. B., et al. (2008) · Neoplasia · doi:10.1593/neo.07822 · Cited by 690
Recurrent gene fusions in prostate cancer
Kumar-Sinha, C., Tomlins, S. A., & Chinnaiyan, A. M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2402 · Cited by 664
Androgen receptor signaling in prostate cancer development and progression
Tindall, D., & Lonergan, P. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.83937 · Cited by 535
ETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice
Tomlins, S. A., Bjartell, A., Chinnaiyan, A. M., Jenster, G., Nam, R. K., Rubin, M. A., & Schalken, J. A. (2009) · European Urology · doi:10.1016/j.eururo.2009.04.036 · Cited by 381
Hessels, D., Smit, F. P., Verhaegh, G. W., Witjes, J. A., Cornel, E. B., & Schalken, J. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0700 · Cited by 334
Metadata
- Authors
- Rajput, A. B., Miller, M. A., De Luca, A., Boyd, N., Leung, S., Hurtado-Coll, A., Fazli, L., Jones, E. C., Palmer, J. B., Gleave, M. E., Cox, M. E., & Huntsman, D. G.
- Venue
- Journal of Clinical Pathology
- Publisher
- BMJ
- Published
- 2007-01-26
- Volume
- 60
- Issue
- 11
- Pages
- 1238-1243
- ISSN
- 0021-9746 (ISSN-L)
- 1472-4146
- OpenAlex
- W1973206059
- Cited by
- 175
- References
- 1
- FWCI
- 16.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. https://app.cochat.ai/papers/10.1136/jcp.2006.043810
- The paper
- Rajput, A. B., Miller, M. A., De Luca, A., Boyd, N., Leung, S., Hurtado-Coll, A., Fazli, L., Jones, E. C., Palmer, J. B., Gleave, M. E., Cox, M. E., & Huntsman, D. G. (2007). Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. Journal of Clinical Pathology. https://doi.org/10.1136/jcp.2006.043810
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.